カテゴリ： Allied Market Research, 世界, 医療/バイオ

医薬品開発及び創薬向け人工知能の世界市場2019–2027：種類別（ターゲット特定、分子スクリーニング、デノボドラッグデザイン・ドラッグ最適化、前臨床・臨床試験）、疾患別、エンドユーザー別

◆英語タイトル：Artificial Intelligence For Drug Development and Discovery Market by Type (Target Identification, Molecule Screening, De Novo Drug Design & Drug Optimization, and Preclinical & Clinical Testing), Indication, (Oncology, Neurology, Infectious Disease and Others), and End User (Pharmaceutical & Biotechnology Companies, and Contract Research Organization): Global Opportunity Analysis and Industry Forecast, 2019–2027
◆商品コード：AMR20PL048
◆発行会社（リサーチ会社）：Allied Market Research
◆発行日：2020年6月
◆ページ数：210
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single UserUSD5,769 ⇒換算￥605,745見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算￥677,250見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算￥944,475見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
※Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。
本調査レポートでは、医薬品開発及び創薬向け人工知能の世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、種類別（ターゲット特定、分子スクリーニング、デノボドラッグデザイン・ドラッグ最適化、前臨床・臨床試験）分析、疾患別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・医薬品開発及び創薬向け人工知能の世界市場規模：種類別（ターゲット特定、分子スクリーニング、デノボドラッグデザイン・ドラッグ最適化、前臨床・臨床試験）
・医薬品開発及び創薬向け人工知能の世界市場規模：疾患別
・医薬品開発及び創薬向け人工知能の世界市場規模：エンドユーザー別
・医薬品開発及び創薬向け人工知能の世界市場規模：地域別
・企業情報

【レポートの概要】

The artificial intelligence for drug discovery and development market was valued at $520 million in 2019 and is projected to reach $4,815 million by 2027, registering a CAGR of 31.6% from 2020 to 2027.

Artificial intelligence (AI) is science and engineering adopted to design intelligent machines, especially intelligent computer programs. AI is an intelligent system that relates various human intelligence based functions such as reasoning, learning, and problem-solving skills on different disciplines such as biology, computer science, psychology, mathematics, linguistics, and engineering. In the healthcare industry, AI is applicable in medication management, treatment plans, drug discovery& developments and others.

Drug discovery& development includes several processes and phases that demand a huge amount of funds. Furthermore, clinical trials and approval of the drug in the market might be a challenging task. Increase in number of collaborations between pharmaceutical & biotech companies and AI providers are the major driver for this market. Artificial intelligence decreases a large amount of time and cost utilized in the drug discovery and development process, which is mainly influencing the market growth. The increasing demand for cloud-based software that enables the researcher to design drugs quickly and accurately is expected to drive the market growth. Moreover, the integration of artificial intelligence (AI) and machine learning approaches within the life science R&D industry is making drug discovery and development more innovative, time-effective and cost-effective.

The artificial intelligence for drug discovery and development market is segmented on the type, indication, end user and region. By type, it is divided into target identification, molecules screening, de novo drug design &drug optimization and preclinical &clinical testing. On the basis of indication, it is classified into oncology, infectious disease, neurology, and others. By end user, it is segmented into pharmaceutical & biotechnology companies, and CROs.

Region wise, the market is analyzed across North America (US, Canada), Europe (Germany, France, UK, Rest of Europe), Asia-Pacific (Japan, China, Australia, India, Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).North America held the major share of the artificial intelligence for drug discovery and development market in 2019 and is expected to continue its dominance during the forecast period, owing to strong economies in the U.S. and Canada; high adoption rate of AI technologies due to large number of investments to boost the drug discovery industry; and large number of cross industry collaborations and partnerships majorly fuels the market growth. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to rise in adoption of advanced AI technologies, and growth in focus of major players on increasing their presence in emerging Asian countries.

KEY MARKET SEGMENTS
By Type
• Target Identification
• Molecule Screening
• De Novo Drug Design and Drug Optimization
• Preclinical and Clinical Testing

By Indication
• Oncology
• Infectious Disease
• Neurology
• Others

By End User
• Pharmaceutical and Biotechnology Companies.
• Contract Research Organization (CROs).

By Geography
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o UK
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
• LAMEA
o Latin America
o Middle East & Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Alphabet Inc.
• Atomwise, Inc
• Benevolent AI
• Cloud Pharmaceutical
• Deep Genomics
• Exscientia
• Insilico Medicine Inc.
• Microsoft Corporation
• Nvidia Corporation

【レポートの目次】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.1. Key benefits for stakeholders
1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Top player positioning, 2019
3.4. Porter’s five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Growing number of cross industry collaborations and partnerships
3.5.1.2. Artificial intelligence reduces cost and time utilized in the drug discovery& development process.

3.5.2. Restraints

3.5.2.1. Lack of skilled professionals
3.5.2.2. Lack of data sets in the field of drug discovery

3.5.3. Opportunity

3.5.3.1. Increase in awareness related to artificial intelligence
3.5.3.2. Untapped market in developing regions

3.5.4. Impact Analysis

CHAPTER 4: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Target Identification

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Molecule Screening

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. De Novo Drug Design and Drug Optimization

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Preclinical and clinical testing

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

CHAPTER 5: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Oncology

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Neurology

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Infectious Disease

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. Others

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

CHAPTER 6: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Pharmaceutical and biotechnology companies

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Contract Research Organization

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America artificial intelligence for drug discovery and development , by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. artificial intelligence for drug discovery and development market, by type
7.2.2.1.2. U.S artificial intelligence for drug discovery and development market, by indication
7.2.2.1.3. U.S. artificial intelligence for drug discovery and development market, by end user

7.2.2.2. Canada

7.2.2.2.1. Canada artificial intelligence for drug discovery and development market, by type
7.2.2.2.2. Canada artificial intelligence for drug discovery and development market, by indication
7.2.2.2.3. Canada artificial intelligence for drug discovery and development market, by end user

7.2.3. North America artificial intelligence for drug discovery and development market, by type
7.2.4. North America artificial intelligence for drug discovery and development , by indication
7.2.5. North America artificial intelligence for drug discovery and development , by end user

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe artificial intelligence for drug discovery and development , by country

7.3.2.1. UK artificial intelligence for drug discovery and development market, by type

7.3.2.1.1. UK artificial intelligence for drug discovery and development market, by type
7.3.2.1.2. UK artificial intelligence for drug discovery and development market, by indication
7.3.2.1.3. UK artificial intelligence for drug discovery and development market, by end user

7.3.2.2. Germany

7.3.2.2.1. Germany artificial intelligence for drug discovery and development market, by type
7.3.2.2.2. Germany artificial intelligence for drug discovery and development market, by indication
7.3.2.2.3. Germany artificial intelligence for drug discovery and development market, by end user

7.3.2.3. France

7.3.2.3.1. France artificial intelligence for drug discovery and development market, by type
7.3.2.3.2. France artificial intelligence for drug discovery and development market, by indication
7.3.2.3.3. France artificial intelligence for drug discovery and development market, by end user

7.3.2.4. Rest of Europe

7.3.2.4.1. Rest of Europe artificial intelligence for drug discovery and development market, by type
7.3.2.4.2. Rest of Europe artificial intelligence for drug discovery and development market, by indication
7.3.2.4.3. Rest of Europe artificial intelligence for drug discovery and development market, by end user

7.3.3. Europe artificial intelligence for drug discovery and development , by type
7.3.4. Europe artificial intelligence for drug discovery and development , by indication
7.3.5. Europe artificial intelligence for drug discovery and development , by end user

7.4. Asia-pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific artificial intelligence for drug discovery and development , by country

7.4.2.1. Japan

7.4.2.1.1. Japan artificial intelligence for drug discovery and development market, by type
7.4.2.1.2. Japan artificial intelligence for drug discovery and development market, by indication
7.4.2.1.3. Japan artificial intelligence for drug discovery and development market, by end user

7.4.2.2. China

7.4.2.2.1. China artificial intelligence for drug discovery and development market, by type
7.4.2.2.2. China artificial intelligence for drug discovery and development market, by indication
7.4.2.2.3. China artificial intelligence for drug discovery and development market, by end user

7.4.2.3. Australia

7.4.2.3.1. .Australia artificial intelligence for drug discovery and development market, by type
7.4.2.3.2. Australia artificial intelligence for drug discovery and development market, by indication
7.4.2.3.3. Australia artificial intelligence for drug discovery and development market, by end user

7.4.2.4. India

7.4.2.4.1. India artificial intelligence for drug discovery and development market, by type
7.4.2.4.2. India artificial intelligence for drug discovery and development market, by indication
7.4.2.4.3. India artificial intelligence for drug discovery and development market, by end user

7.4.2.5. Rest of Asia-Pacific

7.4.2.5.1. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by type
7.4.2.5.2. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by indication
7.4.2.5.3. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by end user

7.4.3. Asia-Pacific artificial intelligence for drug discovery and development , by type
7.4.4. Asia-Pacific artificial intelligence for drug discovery and development , by indication
7.4.5. Asia-Pacific artificial intelligence for drug discovery and development , by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA artificial intelligence for drug discovery and development , by country

7.5.2.1. Latin America

7.5.2.1.1. Latin America artificial intelligence for drug discovery and development market, by type
7.5.2.1.2. Latin America artificial intelligence for drug discovery and development market, by indication
7.5.2.1.3. Latin America artificial intelligence for drug discovery and development market, by end user

7.5.2.2. Middle east and Africa

7.5.2.2.1. Middle east and Africa artificial intelligence for drug discovery and development market, by type
7.5.2.2.2. Middle east and Africa artificial intelligence for drug discovery and development market, by indication
7.5.2.2.3. Middle east and Africa artificial intelligence for drug discovery and development market, by end user

CHAPTER 8: COMPANY PROFILES

8.1. ALPHABET INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. ATOMWISE, INC.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segment
8.2.4. Product portfolio
8.2.5. Key strategic moves and developments

8.3. BENEVOLENT AI

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segment
8.3.4. Product portfolio
8.3.5. Key strategic moves and developments

8.4. CLOUD PHARMACEUTICAL

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Key strategic moves and developments

8.5. DEEP GENOMICS

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segment
8.5.4. Product portfolio

8.6. EXSCIENTIA.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segment
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments

8.7. IBM CORPORATION

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. INSILICO MEDICINE INC.

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segment
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments

8.9. MICROSOFT CORPORATION

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. NVIDIA CORPORATION

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 02. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORTARGET IDENTIFICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 03. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR MOLECULE SCREENING, BY REGION, 2019–2027 ($MILLION)
TABLE 04. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORDE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 05. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 06. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION, 2019–2027($MILLION)
TABLE 07. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY ONCOLOGY, 2019–2027 ($MILLION)
TABLE 08. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY NEUROLOGY, 2019–2027 ($MILLION)
TABLE 09. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY INFECTIOUS DISEASE, 2019–2027 ($MILLION)
TABLE 10. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY OTHERS, 2019–2027 ($MILLION)
TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2019–2027 ($MILLION)
TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY CONTRACT RESEARCH ORGANIZATION, 2019–2027 ($MILLION)
TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 15. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 16. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 17. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 18. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER, 2019-2027 ($MILLION)
TABLE 19. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 20. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 21. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 22. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 23. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 24. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 25. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 26. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 27. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 28. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 29. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 30. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 31. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 32. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 33. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 34. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 35. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 36. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 37. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 38. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 39. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 40. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 41. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 42. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 43. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 44. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 45. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 46. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 47. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 48. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 49. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 50. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 51. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 52. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 53. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 54. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 55. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 56. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 57. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 58. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 59. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 60. LAMEA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)
TABLE 61. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 62. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 63. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 64. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)
TABLE 65. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)
TABLE 66. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)
TABLE 67. ALPHABET INC.: COMPANY SNAPSHOT
TABLE 68. ALPHABET INC.: OPERATING SEGMENTS
TABLE 69. ALPHABET INC.: PRODUCT PORTFOLIO
TABLE 70. ATOMWISE: COMPANY SNAPSHOT
TABLE 71. ATOMWISE: PRODUCT PORTFOLIO
TABLE 72. BENEVOLENT: COMPANY SNAPSHOT
TABLE 73. BENEVOLENT: PRODUCT PORTFOLIO
TABLE 74. CLOUD: COMPANY SNAPSHOT
TABLE 75. CLOUD: PRODUCT PORTFOLIO
TABLE 76. DEEP: COMPANY SNAPSHOT
TABLE 77. DEEP: PRODUCT PORTFOLIO
TABLE 78. EXSCIENTIA: COMPANY SNAPSHOT
TABLE 79. EXSCIENTIA: PRODUCT PORTFOLIO
TABLE 80. IBM CORPORATION: COMPANY SNAPSHOT
TABLE 81. IBM: OPERATING SEGMENTS
TABLE 82. IBM: PRODUCT PORTFOLIO
TABLE 83. INSILICO: COMPANY SNAPSHOT
TABLE 84. INSILICO: PRODUCT PORTFOLIO
TABLE 85. MICROSOFT CORPORATION: COMPANY SNAPSHOT
TABLE 86. MICROSOFT CORPORATION: OPERATING SEGMENTS
TABLE 87. MICROSOFT: PRODUCT PORTFOLIO
TABLE 88. NVIDIA: COMPANY SNAPSHOT
TABLE 89. NVIDIA: OPERATING SEGMENTS
TABLE 90. NVIDIA: PRODUCT PORTFOLIO

【免責事項】
https://www.marketreport.jp/reports-disclaimer
★医療情報レポート[医薬品開発及び創薬向け人工知能の世界市場2019–2027：種類別（ターゲット特定、分子スクリーニング、デノボドラッグデザイン・ドラッグ最適化、前臨床・臨床試験）、疾患別、エンドユーザー別]についてメールでお問い合わせはこちら

※関連の医療情報レポート

  1. 獣医用CROの世界市場：タイプ別（臨床試験、毒性学、市場認可＆規制サポート、その他）、用途別（犬、猫、その他）、エンドユーザー別（腫瘍学、感染症、神経学、その他）
    AMR20FE009 / Allied Market Research / 2019年12月9日 / 本調査レポートでは、獣医用CROの世界市場について調べ、イントロダクション、エグゼクティブサマリー、市場概要、タイプ別（臨床試験、毒性学、市場認可＆規制サポート、その他）分析、用途別（犬、猫、その他）分析、エンドユーザー別（腫瘍学、感染症、神経学、その他）分析、地域別分析、競争状況、企業概要などを総合的、多面的にまとめております。 ・イントロダクション ・エグゼクティブサマリ－ ・市場概要 ・獣医用CROの世界市場：タイプ別（臨床試験、毒性学、市場認可＆規制サポート、その他） ・獣医用CROの世界市場：用途別（犬、猫、その他） ・獣医用CROの世界市場：エンドユーザー別（腫瘍学、感染症、神経学、その他） ・獣医用CROの世界市場：地域別 ・競争状況 ・企業概要...The global veterinary CRO market was valued at $485.5 million in 2018, and is expected to reach $894.7 million by 2026, registering a CAGR of 7.9% from 2019 to 2026. Contract research organizations (CROs) are companies that aid in conducting research for a sponsor company. Moreover, veterinary CROs are companies, which are specialized in in-vivo studies that involve companion animals. Sponsor companies seek provision from veterinary CROs to support research and development programs for biopharmaceutical industries. Furthermore, different types of services are provided by veterinary CROs such as clinical trials, toxicology, and market authorization & regulatory support. These services are...
  2. 医療におけるAIの世界市場2019–2027：提供方式別（ハードウェア、ソフトウェア、サービス）、技術別、用途別、エンドユーザー別
    AMR20PL047 / Allied Market Research / 2020年6月 / 本調査レポートでは、医療におけるAIの世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、提供方式別（ハードウェア、ソフトウェア、サービス）分析、技術別分析、用途別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・医療におけるAIの世界市場規模：提供方式別（ハードウェア、ソフトウェア、サービス） ・医療におけるAIの世界市場規模：技術別 ・医療におけるAIの世界市場規模：用途別 ・医療におけるAIの世界市場規模：エンドユーザー別 ・医療におけるAIの世界市場規模：地域別 ・企業情報...The AI in healthcare market was valued at $4,836.87million in 2019 and is projected to reach $99,491.58 million by 2027, registering a CAGR of 42.8% from 2020 to 2027.Artificial intelligence (AI) can be defined as the science and engineering adopted to design intelligent machines, especially intelligent computer programs. AI is an intelligent system that applies various human intelligence based functions such as reasoning, learning, and problem-solving skills on different disciplines such as biology, computer science, mathematics, linguistics, psychology, and engineering. AI is widely applicable in medication management, treatment plans, and drug discovery. The growth of the AI in healthcare market...
  3. カプノグラフィーの世界市場2020–2027：製品種類別（カプノグラフ（メインストリームカプノグラフ、サイドストリームカプノグラフ、マイクロストリームカプノグラフ）・カプノグラフィー使い捨て品）、用途別、エンドユーザー別
    AMR20PL032 / Allied Market Research / 2020年6月 / 本調査レポートでは、カプノグラフィーの世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、製品種類別（カプノグラフ、カプノグラフィー使い捨て品）分析、用途別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・カプノグラフィーの世界市場規模：製品種類別（カプノグラフ、カプノグラフィー使い捨て品） ・カプノグラフィーの世界市場規模：用途別 ・カプノグラフィーの世界市場規模：エンドユーザー別 ・カプノグラフィーの世界市場規模：地域別 ・企業情報 ...The global capnography market accounted for $393.93 million in 2019, and is expected to reach $1,181.55 million by 2027, registering a CAGR of 13.5% from 2020 to 2027. Capnography is a medical tool that measures concentration or partial pressure of excised or current carbon dioxide. During anesthesia and intensive care, it is mostly used to monitor CO2 in respiratory gases. It also helps to diagnose causes of respiratory distress, provide feedback on treatment effects in real time, and detect shocks. Growth in prevalence of respiratory diseases, rise in surgeries, and increase in geriatric population boosts the market growth. In addition,...
  4. 血液バンクの世界市場2020–2027：製品種類別（全血、赤血球、血小板、血漿、白血球）、機能別、バンクタイプ別、エンドユーザー別
    AMR20JL055 / Allied Market Research / 2020年5月 / 本調査レポートでは、血液バンクの世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、製品種類別（全血、赤血球、血小板、血漿、白血球）分析、機能別分析、バンクタイプ別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場動向 ・血液バンクの世界市場規模：製品種類別（全血、赤血球、血小板、血漿、白血球） ・血液バンクの世界市場規模：機能別 ・血液バンクの世界市場規模：バンクタイプ別 ・血液バンクの世界市場規模：エンドユーザー別 ・血液バンクの世界市場規模：地域別 ・企業情報...The global blood bank market was valued at $13.85 billion in 2019 and is expected to reach $21.86 billion by 2027, registering a CAGR of 5.7% from 2020 to 2027. A blood bank is a non-profit organization that engages in all the operations such as collection, processing, testing, storage, and distribution of blood and blood components drawn from donors. A blood bank can be a separate free-standing organization or operates as a part of a hospital. In addition, a blood bank provides safe or disease-free blood for transfusion to save a patient's life and curb the complications that can arise...
  5. バタフライニードルセットの世界市場2020–2027：用途別（輸血、静脈穿刺、静脈内水分補給、薬剤投与）、エンドユーザー別
    AMR20PL058 / Allied Market Research / 2020年6月 / 本調査レポートでは、バタフライニードルセットの世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、用途別（輸血、静脈穿刺、静脈内水分補給、薬剤投与）分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・バタフライニードルセットの世界市場規模：用途別（輸血、静脈穿刺、静脈内水分補給、薬剤投与） ・バタフライニードルセットの世界市場規模：エンドユーザー別 ・バタフライニードルセットの世界市場規模：地域別 ・企業情報 ...The global butterfly needle blood collection set market was $166.60 million in 2019, and is expected to reach $320.02 million by 2027, registering a CAGR 8.20% from 2020 to 2027. A butterfly needle is a device used to provide access to superficial vein for drawing blood or for an IV injection. These needles are much easier to use and is less painful due to winged tubing structure that allows greater flexibility. In addition, butterfly needles, also known as a winged infusion set or a scalp vein set, are commonly used for babies, young children, and elderly to draw blood or...
  6. 血液の世界市場2020–2027：製品別（全血収集・処理、ソースプラズマコレクション、血液型判定製品、血液スクリーニング製品）、エンドユーザー別
    AMR20JL062 / Allied Market Research / 2020年5月 / 本調査レポートでは、血液の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、製品別（全血収集・処理、ソースプラズマコレクション、血液型判定製品、血液スクリーニング製品）分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場動向 ・血液の世界市場規模：製品別（全血収集・処理、ソースプラズマコレクション、血液型判定製品、血液スクリーニング製品） ・血液の世界市場規模：エンドユーザー別 ・血液の世界市場規模：地域別 ・企業情報...The blood market accounted for $7,201 million in 2020, and is expected to reach $10,253 million by 2027, registering a CAGR of 4.5% from 2020 to 2027. Blood is vital for life and is required for normal functioning of the human body. Furthermore, bone marrow is responsible for the production of blood cells in the body. However, various medical conditions can lead to altered level of blood, which can be fatal for a patient. For instance, medical conditions such as chronic kidney diseases, cancer, and hemophilia B require blood transfusions for treatment. Moreover, in event of a trauma, which causes...
  7. ラテラルフローアッセイの世界市場：製品別（キットおよび試薬、ラテラルフローリーダー）、用途別（臨床試験、獣医診断、食品安全性および環境試験、医薬品開発および品質試験）、手法別（サンドイッチアッセイ、競合アッセイ、多重検出アッセイ）、エンドユーザー別（病院＆クリニック、診断研究所、製薬＆バイオテクノロジー企業、その他）
    BZW9DC025 / Bizwit Research & Consulting / 2019年11月28日 / 当調査レポートでは、ラテラルフローアッセイの世界市場について調査・分析し、エグゼクティブサマリ－、定義・範囲、市場動向、市場分析、製品別（キットおよび試薬、ラテラルフローリーダー）分析、用途別（臨床試験、獣医診断、食品安全性および環境試験、医薬品開発および品質試験）分析、手法別（サンドイッチアッセイ、競合アッセイ、多重検出アッセイ）分析、エンドユーザー別（病院＆クリニック、診断研究所、製薬＆バイオテクノロジー企業、その他）分析、地域別分析、競合状況、調査プロセスなどを含め以下の構成でお届けします。 ・エグゼクティブサマリ－ ・ラテラルフローアッセイの定義・範囲 ・ラテラルフローアッセイ市場動向 ・ラテラルフローアッセイ市場分析 ・ラテラルフローアッセイの世界市場：製品別（キットおよび試薬、ラテラルフローリーダー） ・ラテラルフローアッセイの世界市場：用途別（臨床試験、獣医診断、食品安全性および環境試験、医薬品開発および品質試験） ・ラテラルフローアッセイの世界市場：手法別（サンドイッチアッセイ、競合アッセイ、多重検出アッセイ） ・ラテラルフローアッセイの世界市場：エンドユーザー別（病院＆クリニック、診断研究所、製薬＆バイオテクノロジー企業、その他） ・ラテラルフローアッセイの世界市場：地域別分析...Global Lateral Flow Assay Market is valued approximately at USD 6.0 billion in 2018 and is anticipated to grow with a growth rate of more than 7.6% over the forecast period 2019-2026. Lateral flow Assay, also called lateral flow immunochromatographic assays, are those devices used to detect the presence (or absence) of a target analyte such as biomarkers or pathogens in sample (matrix). Lateral flow assays are mainly used in medical diagnostics for point-of-care testing, home testing and laboratory use. A lateral flow assay strip comprises of conjugate or reagent pad, sample pad, wick or waste reservoir and reaction membrane....
  8. 陰圧創傷治療装置の世界市場2020–2027：製品別（従来型NPWT装置、使い捨てNPWT装置）、用途別、エンドユーザー別
    AMR20JL064 / Allied Market Research / 2020年5月 / 本調査レポートでは、陰圧創傷治療装置の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、製品別（従来型NPWT装置、使い捨てNPWT装置）分析、創傷種類別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場動向 ・陰圧創傷治療装置の世界市場規模：製品別（従来型NPWT装置、使い捨てNPWT装置） ・陰圧創傷治療装置の世界市場規模：創傷種類別 ・陰圧創傷治療装置の世界市場規模：エンドユーザー別 ・陰圧創傷治療装置の世界市場規模：地域別 ・企業情報...The negative pressure wound therapy (NPWT) devices accounted for $2,144 million in 2020, and is expected to reach $3,347 million by 2027, registering a CAGR of 5.7% from 2020 to 2027. Negative pressure wound therapy (NPWT) devices are one of the most commonly used therapies to treat acute and chronic wounds. These devices work by creating negative pressure around the wounds, which leads to the flowing out of exudate from the wound. In addition, NPWT devices promote wound healing, reduce recurrent use of dressings (as in case of traditional wound care), provide an efficient option for management of closed surgical...
  9. 体外診断の世界市場2020–2027：製品・サービス別（試薬、機器、ソフトウェア・サービス）、技術別、用途別、エンドユーザー別
    AMR20PL002 / Allied Market Research / 2020年6月 / 本調査レポートでは、体外診断の世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、製品・サービス別（試薬、機器、ソフトウェア・サービス）分析、技術別分析、用途別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・体外診断の世界市場規模：製品・サービス別（試薬、機器、ソフトウェア・サービス） ・体外診断の世界市場規模：技術別 ・体外診断の世界市場規模：用途別 ・体外診断の世界市場規模：エンドユーザー別 ・体外診断の世界市場規模：地域別 ・企業情報...The global in vitro diagnostics market (IVD) was valued at $67,111 million in 2019, and is projected to reach $91,093 million at a CAGR of 4.8% from 2020 to 2027. In vitro diagnostics (IVD) are defined as medical devices and reagents which are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from human body to detect diseases, conditions, and infections. The tests can be performed in stand-alone laboratory, hospital-based laboratory, and point-of-care centers. Some significant technologies incorporated in in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and...
  10. 医療におけるモノのインターネットの世界市場2020–2027：成分別（デバイス、システム・ソフトウェア、サービス）、用途別、エンドユーザー別
    AMR20PL031 / Allied Market Research / 2020年6月 / 本調査レポートでは、医療におけるモノのインターネットの世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、成分別（デバイス、システム・ソフトウェア、サービス）分析、用途別分析、エンドユーザー別分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・医療におけるモノのインターネットの世界市場規模：成分別（デバイス、システム・ソフトウェア、サービス） ・医療におけるモノのインターネットの世界市場規模：用途別 ・医療におけるモノのインターネットの世界市場規模：エンドユーザー別 ・医療におけるモノのインターネットの世界市場規模：地域別 ・企業情報 ...The global internet of things in healthcare market was valued at $113.7billion in 2019 and is expected to reach $332.67billion by 2027, registering a CAGR of 13.20% from 2020 to 2027. Internet of Things (IoT) is a communication network technology that is rapidly proliferating at an unprecedented rate. It connects people with IoT by transforming information from the physical world into the digital world. It allows the physical devices to connect together to send with computation-based performance in real-world. In addition, in healthcare filed, IoT is used for the data collection, analysis for research, and monitoring electronic health records which...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆